Pharmaceutical Investing Aclaris Therapeutics Announces Availability of ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w)
Alder BioPharmaceuticals Presents New 12-Month Data of Eptinezumab in PROMISE 1 Phase 3 Trial Showing Long-Term Reduction in Episodic Migraine
Medical Device Investing Medtronic Expands Focus on Interventional Oncology with Its U.S. Launch of OptiSphere Embolization Spheres
Pharmaceutical Investing Aclaris Therapeutics Partners with Cipher Pharmaceuticals to seek regulatory approval and commercialize A-101 40% topical solution
Pharmaceutical Investing AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration
Pharmaceutical Investing pSivida Announces FDA Acceptance For Filing of New Drug Application for Durasert
Pharmaceutical Investing U.S. FDA Accepts New Drug Application for Prucalopride for Chronic Idiopathic Constipation
Pharmaceutical Investing Radius Health Reports Fourth Quarter and Full Year 2017 Financial and Operating Results and Provides Business Update
Pharmaceutical Investing Tetraphase Pharmaceuticals Announces FDA Acceptance for Filing of its NDA Submission for Eravacycline
Medical Device Investing REVA Announces CE Mark and First Implant of the Fantom Encore Bioresorbable Scaffold
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2017
Pharmaceutical Investing ContraVir Pharmaceuticals Announces TXL Has Been Granted Orphan Drug Designation for the Treatment of HBV in a Pediatric Population
